4 Results for "

F-actin ring

" in MedChemExpress (MCE) Product Catalog:
Products (4)

4 Results for "F-actin ring" in MCE Product Catalog:

5
Epimedin B
Epimedin B
0 Images
5 Cited Publications
Cat. No.: HY-N0259
CAS No.: 110623-73-9
Synonyms: Epmedin B
Category:  

Flavonols Plant Flavonoids Monophenols Epimedium brevicornu Maxim. Extract Other Diseases Phenols Disease Research Fields Berberidaceae Extract

Target:  

JNK Estrogen Receptor/ERR p38 MAPK PI3K Akt AMPK Keap1-Nrf2 Reactive Oxygen Species (ROS) Apoptosis Bcl-2 Family

Epimedin B (Epmedin B) is a flavonoid active component found in Epimedium, with oral activity, and exhibits anti-osteoporotic and neuroprotective effects. Epimedin B inhibits RANKL-induced osteoclast differentiation, F-actin ring formation, and mature osteoclast bone resorption, inhibits the phosphorylation of JNK, p38 MAPK, PI3K, and AKT, activates the AMPK-Nrf2 antioxidant pathway, and reduces cellular and mitochondrial ROS. Epimedin B acts on ESR1 and exerts its effects via GPER. Epimedin B alleviates bone loss and improves bone microstructure in vivo, and in Parkinson's models protects dopaminergic neurons and maintains striatal dopamine levels through anti-apoptotic and anti-endoplasmic reticulum stress effects. Epimedin B can be used for research related to osteoporosis, diabetic osteoporosis, and Parkinson's disease .
loading...
    loading...
View All Sizes
E0924G
E0924G
0 Images
Cat. No.: HY-168336
CAS No.: 2909474-29-7
Target:  

PPAR

Research Areas:  

Metabolic Disease

E0924G is an orally active activator for PPARδ with EC50 of 2.82 μM. E0924G promotes the upregulation of osteoprotegerin (OPG) with an EC50 of 0.29 μM. E0924G reduces RANKL-induced osteoclast differentiation and inhibites F-actin ring formation in RAW264.7 macrophages. E0924G regulates the bone density and bone loss in ovariectomized (OVX) and age-related osteoporosis models .
loading...
    loading...
View All Sizes
Epimedin B (Standard)
Epimedin B (Standard)
0 Images
Cat. No.: HY-N0259R
CAS No.: 110623-73-9
Synonyms: Epmedin B (Standard)
Category:  

Flavonols Plant Flavonoids Monophenols Epimedium brevicornu Maxim. Extract Phenols Berberidaceae Extract

Target:  

Reference Standards JNK Estrogen Receptor/ERR p38 MAPK PI3K Akt AMPK Keap1-Nrf2 Reactive Oxygen Species (ROS) Apoptosis Bcl-2 Family

Epimedin B (Standard) (Epmedin B (Standard)) is the analytical standard of Epimedin B (HY-N0259). This product is intended for research and analytical applications. Epimedin B (Epmedin B) is a flavonoid active component found in Epimedium, with oral activity, and exhibits anti-osteoporotic and neuroprotective effects. Epimedin B inhibits RANKL-induced osteoclast differentiation, F-actin ring formation, and mature osteoclast bone resorption, inhibits the phosphorylation of JNK, p38 MAPK, PI3K, and AKT, activates the AMPK-Nrf2 antioxidant pathway, and reduces cellular and mitochondrial ROS. Epimedin B acts on ESR1 and exerts its effects via GPER. Epimedin B alleviates bone loss and improves bone microstructure in vivo, and in Parkinson's models protects dopaminergic neurons and maintains striatal dopamine levels through anti-apoptotic and anti-endoplasmic reticulum stress effects. Epimedin B can be used for research related to osteoporosis, diabetic osteoporosis, and Parkinson's disease .
loading...
    loading...
View All Sizes
Y1693
Y1693
0 Images
Cat. No.: HY-182757
CAS No.: 2812381-74-9
Target:  

RANKL/RANK Nuclear Factor of activated T Cells (NFAT) Cathepsin

Research Areas:  

Metabolic Disease Inflammation/Immunology

Y1693 is an orally active RANKL inhibitor with a Kd of 5.03 μM for hRANKL. Y1693 inhibits the activation of the downstream c-fos/NFATc1 signaling pathway by blocking its interaction with RANK. Y1693 significantly inhibits RANKL-induced osteoclast differentiation, F-actin ring formation and bone resorptive activity, while downregulating the mRNA and protein expressions of TRAP, cathepsin K, c-fos and NFATc1. Y1693 shows no obvious cytotoxicity to bone marrow-derived macrophages and osteoclast precursor cells, and exhibits favorable ADME properties. Y1693 improves ovariectomy-induced osteoporosis in mice and reverses ligation-induced periodontal alveolar bone loss. Y1693 is applicable to research related to osteoporosis and periodontal diseases .
loading...
    loading...
View All Sizes
Assay Types